NT5E Protein

Introduction

CD73 (Cluster of Differentiation 73), also known as Ecto-5’-Nucleotidase (NT5E), is a glycosylphosphatidylinositol (GPI)-anchored cell surface enzyme that catalyzes the hydrolysis of extracellular nucleotides to adenosine. As the rate-limiting enzyme in adenosine production, CD73 plays pivotal roles in purinergic signaling, immune regulation, neuroprotection, and cellular energy balance. This protein is widely expressed in the central nervous system (CNS), where it modulates synaptic transmission, neuroinflammation, and blood-brain barrier (BBB) function.

--- ^{1- CD73 and adenosine in Alzheimer's diseasePMID 28947065Open reference} title: NT5E Protein ^{2- A2A receptors in Parkinson's diseasePMID 28455230Open reference} description: Protein page for CD73 / Ecto-5’-Nucleotidase ^{3- CD73 in neuroinflammation and multiple sclerosisPMID 31270389Open reference}

--- ^{4- CD73 structure and mechanismPMID 29843652Open reference}

Overview

flowchart TD
    NT5E["NT5E"] -->|"regulates"| Alzheimer["Alzheimer"]
    NT5E["NT5E"] -->|"regulates"| Als["Als"]
    NT5E["NT5E"] -->|"regulates"| Dementia["Dementia"]
    NT5E["NT5E"] -->|"regulates"| Inflammation["Inflammation"]
    NT5E["NT5E"] -->|"expressed in"| Dementia["Dementia"]
    NT5E["NT5E"] -->|"expressed in"| Alzheimer["Alzheimer"]
    NT5E["NT5E"] -->|"expressed in"| Als["Als"]
    NT5E["NT5E"] -->|"expressed in"| NLRP3["NLRP3"]
    NT5E["NT5E"] -->|"expressed in"| HSP90AA1["HSP90AA1"]
    NT5E["NT5E"] -->|"associated with"| P2RX7["P2RX7"]
    NT5E["NT5E"] -->|"regulates"| Lipid_Metabolism["Lipid Metabolism"]
    NT5E["NT5E"] -->|"expressed in"| Lipid_Metabolism["Lipid Metabolism"]
    NT5E["NT5E"] -->|"expressed in"| Cytokine["Cytokine"]
    P2RX7["P2RX7"] -->|"expressed in"| NT5E["NT5E"]
    style NT5E fill:#4fc3f7,stroke:#333,color:#000

CD73 is a glycosylphosphatidylinositol (GPI)-anchored enzyme that converts extracellular AMP to adenosine. As the rate-limiting enzyme in adenosine production, CD73 plays critical roles in purinergic signaling, immune regulation, neuroprotection, and synaptic transmission. CD73 hydrolyzes extracellular AMP to adenosine, producing the majority of extracellular adenosine in tissues. This adenosine signals through purinergic receptors (A1, A2A, A2B, A3) to modulate synaptic transmission, neuronal excitability, and glial function. CD73 is essential for astrocyte-neuron metabolic coupling, microglial surveillance, and blood-brain barrier regulation.

Protein Structure

Domain Architecture

CD73 is a homodimeric enzyme with each subunit containing:

• N-terminal domain (~320 aa): Catalytic site with metal-binding motifs

• C-terminal domain (~280 aa): Dimerization and substrate binding

• GPI anchor: C-terminal attachment to plasma membrane

Catalytic Mechanism

• Requires zinc ions (Zn²⁺) for activity

• Two-step hydrolysis: AMP → adenosine + phosphate

• Rate-limiting step in adenosine production

• Allosteric regulation by nucleotides

Post-Translational Modifications

Normal Function

Purinergic Signaling

CD73 is the primary source of extracellular adenosine:

• Hydrolyzes AMP to adenosine

• Regulates purinergic receptor activation

• Modulates synaptic plasticity

• Controls neuronal excitability

Adenosine Receptor Signaling

Neurophysiological Roles

• Synaptic transmission: Modulates glutamate and GABA release

• Metabolic coupling: Astrocyte-neuron adenosine signaling

• Sleep-wake cycle: Adenosine accumulation promotes sleep

• Microglial surveillance: Basal adenosine tone

Immune Regulation

• Inhibits T cell activation

• Promotes regulatory T cell function

• Modulates macrophage polarization

• Anti-inflammatory in chronic disease

Expression in the CNS

Cell Type Distribution

Role in Disease

Alzheimer’s Disease

In Alzheimer’s disease:

• Reduced CD73 activity in AD brains

• Adenosine deficiency contributes to cognitive impairment

• Aβ affects CD73 expression on glia

• Therapeutic potential of CD73 modulation

Parkinson’s Disease

In Parkinson’s disease:

• A2A receptor antagonists (caffeine) reduce PD risk

• CD73 modulates dopaminergic neuron survival

• Adenosine signaling in basal ganglia

• Therapeutic target for motor symptoms

Multiple Sclerosis

In multiple sclerosis:

• CD73 deficiency on T cells

• Immune tolerance via adenosine

• Demyelination and remyelination

• Therapeutic target

Stroke and Ischemia

Following cerebral ischemia:

• CD73-derived adenosine is neuroprotective

• A1 receptor activation reduces infarct size

• Post-ischemic inflammation modulation

Cancer

• Overexpression in many tumors

• Immunosuppressive adenosine production

• Target for cancer immunotherapy

Therapeutic Implications

Drug Development

Potential Neurodegeneration Applications

• Adenosine enhancement strategies

• A2A receptor modulation

• BBB-penetrant compounds

Research Tools

Antibodies

• Anti-CD73 (CD39/CD73 panel)

• Functional blocking antibodies

• Flow cytometry panels

Mouse Models

• NT5E knockout mice

• Conditional deletion in CNS

• Transgenic overexpression

Assays

• Enzyme activity (colorimetric, fluorometric)

• Adenosine measurement (HPLC, mass spec)

• Receptor binding studies

See Also

• Proteins Index

• NT5E Gene

• Purinergic Signaling Pathway

• Adenosine Signaling

• Neuroinflammation Pathway

• Astrocytes

• Microglia

Background

The study of Nt5E Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• UniProt - NT5E

• PDB - CD73

• NCBI Protein - NT5E

• GeneCards - NT5E